RBC Capital analyst Conor McNamara maintained a Buy rating on QuidelOrtho (QDEL – Research Report) on January 5 and set a price target of $125.00. The company’s shares closed yesterday at $90.77. McNamara covers the Healthcare sector, focusing on stocks such as QuidelOrtho, Illumina, and Bio-Rad Laboratories. According to TipRanks, McNamara has an average return of 2.8% and a 66.67% success rate on recommended stocks.  The word on The Street in general, suggests a Moderate Buy analyst consensus rating for QuidelOrtho with a $113.00 average price target. See today’s best-performing stocks on TipRanks >> Based on QuidelOrtho’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $783.8 million and a net profit of $19.2 million. In comparison, last year the company earned a revenue of $509.8 million and had a net profit of $215.7 million
		  TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Quidel Corp. engages in the development, manufacture and market of rapid diagnostic testing solutions. Its portfolio includes rapid immunoassays, cardiac immunoassays, specialized diagnostic solutions and molecular diagnostic solutions. The products are directly sold to end users and distributors and for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies and wellness screening centers. The company was founded in 1979 and is headquartered in San Diego, CA.  Read More on QDEL: Indices Commodities Currencies Stocks